Allan R. Moorman

Suicide inactivation of chymotrypsin by benzoxazinones

Lizbeth Hedstrom, Allan R. Moorman, Jeffrey Dobbs et al. · Biochemistry · 1984 · 103 citations

Pharmacy, Pharmacology, Drug Discovery +4

Design, Synthesis, and Biological Evaluation of New 8-Heterocyclic Xanthine Derivatives as Highly Potent and Selective Human A_2BAdenosine Receptor Antagonists

Pier Giovanni Baraldi, Mojgan Aghazadeh Tabrizi, Delia Preti et al. · Journal of Medicinal Chemistry · 2004 · 98 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Design, Synthesis, and Biological Evaluation of C⁹- and C²-Substituted Pyrazolo[4,3-<i>e</i>]-1,2,4-triazolo[1,5-<i>c</i>]pyrimidines as New A_2Aand A₃Adenosine Receptors Antagonists

Pier Giovanni Baraldi, Francesca Fruttarolo, Mojgan Aghazadeh Tabrizi et al. · Journal of Medicinal Chemistry · 2003 · 74 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

New class of serine protease inactivators based on isatoic anhydride

Allan R. Moorman, Robert H. Abeles · Journal of the American Chemical Society · 1982 · 70 citations

Life Sciences, Biochemistry, Chemistry +7

N6-[(Hetero)aryl/(cyclo)alkyl-carbamoyl-methoxy-phenyl]-(2-chloro)-5′-N-ethylcarboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A2B adenosine receptor

Pier Giovanni Baraldi, Delia Preti, Mojgan Aghazadeh Tabrizi et al. · Bioorganic & Medicinal Chemistry · 2007 · 65 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13